Defendant Name: DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)

Defendant Type: Public Company

Document Reference: 33-11353-s

Document Details

Legal Case Name In the Matter of DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation) and Robert O. Hopkins
Document Name SEC Sues Pharmaceutical Company for Accounting and Disclosure Fraud and Bars Its Former Chief Financial Officer
Document Date 14-Jan-2025
Document Format Administrative Proceeding
File Number 3-22416
Allegation Type Issuer Reporting and Disclosure
Document Summary On January 14, 2025, the SEC "announced settled charges against DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals("Adamis") and Robert O. Hopkins ("Hopkins"), its former Chief Financial Officer, for a fraudulent scheme to generate revenues using illegal prescriptions."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Monetary Penalties:

Disgorgement

(Penalty was noted in document, but no amount was listed)

Pre-Judgment Interest

(Penalty was noted in document, but no amount was listed)

Total Penalty

Individual:     $334,314.00 Shared:    

Related Documents:

33-11353 14-Jan-2025 Administrative Proceeding
Order Instituting Administrative and Cease-and-Desist Proceedings, Pursuant to Section 8A of the Securities Act of 1933, Sections 4C and 21C of the Securities Exchange Act of 1934, and Rule 102(e) of the Commission's Rules of Practice, Making Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order
On January 14, 2025, the SEC instituted settled administrative and cease-and-desist proceedings against DMK Pharmaceuticals Corporation, formerly known as Adamis Pharmaceuticals Corporation, and Robert O. Hopkins, stating: "These proceedings arise out of an accounting and disclosure fraud case concerning DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals Corporation (“DMK Pharmaceuticals” or “Adamis”) and Robert O. Hopkins, its former Chief Financial Officer."

Other Defendants in Action:

Robert O. Hopkins